1. Academic Validation
  2. Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection

Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection

  • Sci Rep. 2022 May 12;12(1):7843. doi: 10.1038/s41598-022-11879-1.
Maria L Faquetti 1 Francesca Grisoni 1 2 Petra Schneider 1 3 Gisbert Schneider 1 3 4 Andrea M Burden 5
Affiliations

Affiliations

  • 1 Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
  • 2 Department of Biomedical Engineering, Institute for Complex Molecular Sciences, Eindhoven University of Technology, Eindhoven, The Netherlands.
  • 3 inSili.com LLC, Zurich, Switzerland.
  • 4 ETH Singapore SEC Ltd, Singapore, 138602, Singapore.
  • 5 Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. andrea.burden@pharma.ethz.ch.
Abstract

As there are no clear on-target mechanisms that explain the increased risk for thrombosis and viral Infection or reactivation associated with JAK inhibitors, the observed elevated risk may be a result of an off-target effect. Computational approaches combined with in vitro studies can be used to predict and validate the potential for an approved drug to interact with additional (often unwanted) targets and identify potential safety-related concerns. Potential off-targets of the JAK inhibitors baricitinib and tofacitinib were identified using two established machine learning approaches based on ligand similarity. The identified targets related to thrombosis or viral Infection/reactivation were subsequently validated using in vitro assays. Inhibitory activity was identified for four drug-target pairs (PDE10A [baricitinib], TRPM6 [tofacitinib], PKN2 [baricitinib, tofacitinib]). Previously unknown off-target interactions of the two JAK inhibitors were identified. As the proposed pharmacological effects of these interactions include attenuation of pulmonary vascular remodeling, modulation of HCV response, and hypomagnesemia, the newly identified off-target interactions cannot explain an increased risk of thrombosis or viral Infection/reactivation. While further evidence is required to explain both the elevated thrombosis and viral Infection/reactivation risk, our results add to the evidence that these JAK inhibitors are promiscuous binders and highlight the potential for repurposing.

Figures
Products